Allos Therapeutics has announced the publication of results from its Phase II multicenter study of efaproxyn in patients with unresectable non-small cell lung cancer (NSCLC) receiving sequential chemoradiotherapy (S-CRT). Results from the study, which were reported in the Journal of Clinical Oncology, suggest that the addition of efaproxyn to S-CRT may improve survival over S-CRT alone without increasing radiation toxicity rates.
Authors of the manuscript compared the safety and efficacy of the drug when administered with S-CRT in patients with unresectable NSCLC relative to data from a Phase III, Radiation Therapy Oncology Group (RTOG) 94-10 study. Results of the analysis indicate that patients in the study tended to have better survival than patients with similar characteristics in the RTOG 94-10 study. Median survival of patients treated in the efaproxyn study was 20.6 months, as compared to a median survival of 15.1 months for patients in the S-CRT arm of the RTOG 94-10 study and 17.9 months in the concurrent chemoradiotherapy arm of the RTOG 94-10 study.